FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [®]					2. Issuer Name and Ticker or Trading Symbol Pacira Pharmaceuticals, Inc. [PCRX]										5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last)	(Fi	rst) (3. Date of Earliest Transaction (Month/Day/Year) 06/15/2016								1	X Direct Offic below	er (give title		Owner (specify)		
C/O PACIRA PHARMACEUTICALS, INC. 5 SYLVAN WAY, SUITE 300					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. I Lin	- /			
(Street)	PANY N.	J (07054													i filed by Mor	e Reporting Pe e than One Re	
(City)	(S	tate) (Zip)															
		Tab	le I - Non	n-Deriva	ative S	Secu	ıritie	s Ac	quired, [Disp	osed	of, or l	Bene	ficia	lly Owne	ed		
Date				Transacti ate Ionth/Day	Execution D			Date,	Code (Instr.		4. Securities Acquired (Disposed Of (D) (Instr. 3 and 5)				r 5. Am Secur Benef Ownee Follow	icially d	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
								Code	v	Amour	nt (A (D) or)	Price	Repor Trans		(1150.4)	(IIISU: 4)	
Common Stock 06/15/20				016	16		Α		1,48	8(1)	A	\$ <mark>0.0</mark>	00	3,788	D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	rcise (Month/Day/Year) if any f ive (Month/Day/Yea		Date, T C ly/Year) 8	4. Transaction Code (Instr. 8) Code V		Number of Upervalve Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Date Exercisable and Expiration Date Month/Day/Year) Date Expiration Exercisable Date			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) Amoun or Numbe of Shares		. 3 Dunt Iber	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

\$40.34

1. Represents restricted stock units that vest on June 3, 2017, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

(2)

2. The stock option vests and becomes exercisable on the first anniversary of the grant date, provided that the reporting person remains in continuous service with the issuer through the vesting date.

Remarks:

Option

Buy)

(Right to

/s/ James Scibetta, Attorney-	0
in-Fact	<u>U</u>

2,975

\$0.00

Common

Stock

06/15/2026

06/17/2016

2.975

D

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

06/15/2016

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.